Article
Oncology
Jian Wu, Emily Chu, Barry Paul, Yubin Kang
Summary: This study analyzed the drug-to-drug interactions between immunomodulatory drugs and peroxisome proliferator-activated receptor agonists in multiple myeloma. The results showed that peroxisome proliferator-activated receptor agonists reduced CRBN expression by inducing DNA methylation and increasing protein degradation. Co-administration of immunomodulatory drugs and peroxisome proliferator-activated receptor agonists was associated with inferior treatment responses and poor survival.
Article
Oncology
Motiur Rahman, Alissa Keegan, Jazmine Mateus, Christopher Kim
Summary: This study evaluated the prognostic performance of different risk stratification systems in newly diagnosed multiple myeloma patients. The results showed that the Revised International Staging System (R-ISS) had better predictive accuracy in assessing patient risk and could be implemented in a real-world clinical setting, providing a basis for personalized treatment.
LEUKEMIA & LYMPHOMA
(2023)
Article
Clinical Neurology
Yuri Ahuja, Nicole Kim, Liang Liang, Tianrun Cai, Kumar Dahal, Thany Seyok, Chen Lin, Sean Finan, Katherine Liao, Guergana Savovoa, Tanuja Chitnis, Tianxi Cai, Zongqi Xia
Summary: Currently, there is no relapse risk prediction tool available for guiding treatment selection in multiple sclerosis (MS). Leveraging electronic health record (EHR) data, a novel machine-learning algorithm was developed to predict 1-year MS relapse risk. The algorithm accurately predicted MS relapse and may have potential applications in other neurological diseases beyond MS.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2021)
Article
Oncology
Shakira J. Grant, Tanya M. Wildes, Ashley E. Rosko, Juliet Silberstein, Smith Giri
Summary: This study analyzed a database of 7512 newly diagnosed multiple myeloma patients and found that early mortality mainly occurred in patients aged 70 years and above. Factors associated with higher odds of early mortality included patients' performance status, disease stage, age, treatment regimen, renal function, and disease progression. For older adults aged 70 years and above, performance status and disease stage remained the strongest predictors of early mortality.
Article
Hematology
Annabel McMillan, Supratik Basu, Kamaraj Karunanithi, Elizabeth Parkins, Edward Yan Ming Lau, Gordon Cook, Christopher Parrish, Firas Al-Kaisi, Guy Pratt, Salim Shafeek, Stephen Jenkins, Danish Memon, Ceri Bygrave, Xenofon Papanikolaou, Tara Maisel, Sandra Hassan, Shivir Moosai, Gurvin Chander, Pallav Rakesh, Bhuvan Kishore, Farheen Karim, Georgina Talbot, Farooq Wandroo, Kwee Yong, Rakesh Popat
Summary: This study evaluates the overall response rate (ORR) and progression-free survival (PFS) in routine clinical practice for patients with first relapse multiple myeloma treated with daratumumab, bortezomib, and dexamethasone (DVd). The results show that DVd is effective in a heterogeneous real-world population at first relapse, with a low rate of peripheral neuropathy. However, high-risk patients have inferior outcomes and alternative treatments should be considered.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Clinical Neurology
Prakash Adekkanattu, Mark Olfson, Leah C. Susser, Braja Patra, Veer Vekaria, Brandon J. Coombes, Lauren Lepow, Brian Fennessy, Alexander Charney, Euijung Ryu, Kurt D. Miller, Lifang Pan, Tenzin Yangchen, Ardesheer Talati, Priya Wickramaratne, Myrna Weissman, John Mann, Joanna M. Biernacka, Jyotishman Pathak
Summary: This study used clinical data from the INSIGHT Clinical Research Network in New York City to examine comorbidities and healthcare utilization in patients with treatment resistant depression (TRD). The results showed that TRD patients had higher rates of anxiety disorder and physical comorbidities, as well as increased emergency room visits and inpatient stays compared to non-TRD major depressive disorder (MDD) patients.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Health Care Sciences & Services
Freya Tyrer, Krishnan Bhaskaran, Mark J. Rutherford
Summary: This study investigated immortal time bias for a specific life-long condition, intellectual disability, using the Clinical Practice Research Datalink (CPRD). The results show that immortal time bias is a significant issue for studies of life-long conditions that use electronic health record data and careful consideration of clinical diagnoses entry is needed.
BMC MEDICAL RESEARCH METHODOLOGY
(2022)
Review
Public, Environmental & Occupational Health
Ingridy M. P. Barbalho, Felipe Fernandes, Daniele M. S. Barros, Jailton C. Paiva, Jorge Henriques, Antonio H. F. Morais, Karilany D. Coutinho, Giliate C. Coelho Neto, Arthur Chioro, Ricardo A. M. Valentim
Summary: This paper presents an audit of the main approaches used for Electronic Health Records (EHR) development in Brazil, discussing prospects, challenges, and existing gaps. The analysis highlights the importance of interoperability, data security, and defined development methodologies.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Computer Science, Information Systems
Joanna Harton, Nandita Mitra, Rebecca A. Hubbard
Summary: The study found that using biomarker values collected at informative and noninformative visits can reduce bias when the biomarker is stable over time, but may lead to substantial bias when it is volatile. Adjusting for the number of prior visits within a fixed look-back window can help mitigate bias to some extent, but not eliminate it completely. Bias may frequently occur in common scenarios and adjusting for prior visit intensity may not always be effective in eliminating it.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
(2022)
Article
Urology & Nephrology
Atlas Khan, Ning Shang, Lynn Petukhova, Jun Zhang, Yufeng Shen, Scott J. Hebbring, Halima Moncrieffe, Leah C. Kottyan, Bahram Namjou-Khales, Rachel Knevel, Soumya Raychaudhuri, Elizabeth W. Karlson, John B. Harley, Ian B. Stanaway, David Crosslin, Joshua C. Denny, Mitchell S. V. Elkind, Ali G. Gharavi, George Hripcsak, Chunhua Weng, Krzysztof Kiryluk
Summary: This study identified genetic determinants of plasma C3 and C4 levels using eMERGE genomic data linked to electronic medical records. Genetic variants regulating C3 and C4 levels have large effects and multiple clinical correlations across a spectrum of complement-related diseases in humans.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2021)
Article
Multidisciplinary Sciences
Chengxi Zang, Yongkang Zhang, Jie Xu, Jiang Bian, Dmitry Morozyuk, Edward J. Schenck, Dhruv Khullar, Anna S. Nordvig, Elizabeth A. Shenkman, Russell L. Rothman, Jason P. Block, Kristin Lyman, Mark G. Weiner, Thomas W. Carton, Fei Wang, Rainu Kaushal
Summary: In this study, the authors used electronic health records to characterize post-acute sequelae of SARS-CoV-2 infection and found possible heterogeneity between populations. They identified a broad range of PASC-related conditions and replicated some of them across two cohorts.
NATURE COMMUNICATIONS
(2023)
Article
Medicine, General & Internal
Liping Li, Xiaofeng Li, An Shang, Yan Zhao, Lifang Jin, Meng Zhao, Weizhang Shen
Summary: This study aimed to examine the prognostic significance of CD56 in patients with multiple myeloma (MM). The results showed that MM patients with CD56 negativity had worse prognosis in terms of overall response rate, progression-free survival (PFS), and overall survival (OS).
Article
Integrative & Complementary Medicine
Yunfeng Lai, Ruoning Wang, Wei Li, He Zhu, Shuyang Fei, Honghao Shi, Nan Lu, Carolina Oi Lam Ung, Hao Hu, Sheng Han
Summary: This study analyzed the clinical and economic effects of Gastrodin injection for patients with dizziness or vertigo. The results showed that Gastrodin injection had better treatment effect and lower hospitalization costs compared to Extract of Ginkgo Biloba Leaves injection.
Article
Computer Science, Information Systems
Inyoung Jun, Shannan N. Rich, Zhaoyi Chen, Jiang Bian, Mattia Prosperi
Summary: Replicating prediction models using EHR data, especially for MRSA outcomes, is challenging due to the lack of well-defined computable phenotypes for predictors and outcomes. While most original variables can be (re)computed, certain variables may only be approximated by proxy computable phenotypes, leading to mild discriminatory ability in the replicated prediction model. Despite the richness of EHR data, limited availability of validated computable phenotypes remains a challenge when replicating complex prediction models.
INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS
(2021)
Article
Public, Environmental & Occupational Health
Ze Luan, Zhiru Zhang, Yanan Gao, Shiyuan Du, Nan Wu, Yulu Chen, Xin Peng
Summary: This study conducted a bibliometric analysis on the application of electronic health records in the nursing field from 2000 to 2020. The results showed an increasing trend in the quantity of publications and research hotspots. The analysis of author collaboration networks and research topics provided a reference for the effective use of electronic health records in nursing.
FRONTIERS IN PUBLIC HEALTH
(2023)
Article
Hematology
Jesus San-Miguel, Herve Avet-Loiseau, Bruno Paiva, Shaji Kumar, Meletios A. Dimopoulos, Thierry Facon, Maria-Victoria Mateos, Cyrille Touzeau, Andrzej Jakubowiak, Saad Z. Usmani, Gordon Cook, Michele Cavo, Hang Quach, Jon Ukropec, Priya Ramaswami, Huiling Pei, Mia Qi, Steven Sun, Jianping Wang, Maria Krevvata, Nikki DeAngelis, Christoph Heuck, Rian Van Rampelbergh, Anupa Kudva, Rachel Kobos, Ming Qi, Nizar J. Bahlis
Summary: In patients with transplant-ineligible newly diagnosed multiple myeloma, daratumumab-based therapy reduces the risk of disease progression or death. MRD-negative status and sustained MRD negativity are associated with improved progression-free survival, and daratumumab-based therapy improves rates of MRD negativity lasting 6 or 12 months.
Article
Hematology
Saad Z. Usmani, Hareth Nahi, Wojciech Legiec, Sebastian Grosicki, Vladimir Vorobyev, Ivan Spicka, Vania Hungria, Sibirina Korenkova, Nizar J. Bahlis, Max Flogegard, Joan Blade, Philippe Moreau, Martin Kaiser, Shinsuke Iida, Jacob Laubach, Hila Magen, Michele Cavo, Cyrille Hulin, Darrell White, Valerio De Stefano, Kristen Lantz, Lisa O'Rourke, Christoph Heuck, Maria Delioukina, Xiang Qin, Ivo Nnane, Ming Qi, Maria-Victoria Mateos
Summary: This study reports the efficacy and safety of daratumumab administered subcutaneously or intravenously in patients with relapsed or refractory multiple myeloma. With longer follow-up, both administration methods showed consistent efficacy and maximum drug concentration, with a good safety profile.
Article
Oncology
Thomas Martin, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Deepu Madduri, Andrzej Jakubowiak, Yi Lin, Sundar Jagannath
Summary: PURPOSECARTITUDE-1, a phase Ib/II study, evaluated the safety and efficacy of Ciltacabtagene Autoleucel in heavily treated patients with relapsed/refractory multiple myeloma. The study showed early, deep, and durable responses at 12 months, with updated results at 2 years. Patients received a single infusion of Ciltacabtagene Autoleucel and responses were assessed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
David M. Foureau, Barry A. Paul, Fei Guo, Edward H. Lipford, Kateryna Fesenkova, Elise Tjaden, Kendra Drummond, Manisha Bhutani, Shebli Atrash, Ami Ndiaye, Cindy Varga, Peter M. Voorhees, Saad Z. Usmani
Summary: To optimize specimen adequacy, our institution standardized technical 1st pull bone marrow aspirates (BMA) for minimal residual disease (MRD) testing in multiple myeloma. We achieved an analytical assay input of 10 million nucleated cells for 97.5% of specimens, allowing us to routinely achieve 1-2 x 10 -6 analytic sensitivity.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Oncology
Adam D. Cohen, Parameswaran Hari, Myo Htut, Jesus G. Berdeja, Saad Z. Usmani, Deepu Madduri, Yunsi Olyslager, Jenna D. Goldberg, Jordan M. Schecter, Carolyn C. Jackson, Katharine S. Gries, John M. Fastenau, Satish Valluri, William Deraedt, Muhammad Akram, Rebecca Crawford, Ross Morrison, Lynda Doward, Kate Morgan, Silene ten Seldam, Andrzej Jakubowiak, Sundar Jagannath
Summary: Ciltacabtagene autoleucel (cilta-cel) is a CAR-T cell therapy that has shown efficacy in patients with relapsed/refractory multiple myeloma and improvements in health-related quality of life. Patient perspectives on cilta-cel treatment provide additional context to clinical outcomes and the majority of patients reported that their expectations were met or exceeded.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Article
Medicine, General & Internal
Tom Martin, Saad Z. Usmani, Jordan M. Schecter, Tito Roccia, Carolyn C. Jackson, William Deraedt, Tzu-Min Yeh, Arnob Banerjee, Lida Pacaud, Ashraf Garrett, Meaghan Bartlett, Anja Haltner, Suzy Van Sanden, Joris Diels, Satish Valluri, Imtiaz A. Samjoo
Summary: This study compared the efficacy of cilta-cel and ide-cel in treating RRMM patients using the latest clinical trial data. The results demonstrated that cilta-cel had significantly improved overall response rate, complete response rate, duration of response, progression-free survival, and overall survival compared to ide-cel.
CURRENT MEDICAL RESEARCH AND OPINION
(2023)
Article
Hematology
Matthew J. J. Pianko, Timothy Tiutan, Andriy Derkach, Jessica Flynn, Steven P. P. Salvatore, Insara Jaffer-Sathick, Adriana C. C. Rossi, Oscar Lahoud, Malin Hultcrantz, Urvi A. A. Shah, Kylee Maclachlan, David J. J. Chung, Gunjan L. L. Shah, Heather J. J. Landau, Neha Korde, Sham Mailankody, Alexander M. M. Lesokhin, Carlyn Tan, Michael Scordo, Edgar A. A. Jaimes, Sergio A. A. Giralt, Saad Usmani, Hani Hassoun
Summary: This retrospective analysis of patients with monoclonal immunoglobulin deposition disease (MIDD) demonstrates that renal response can be captured using both estimated glomerular filtration rate (eGFR) and proteinuria criteria. Most patients achieved a very good partial hematologic response with treatment. Isolated proteinuria may be an early manifestation of MIDD associated with reversible renal damage. Baseline eGFR predicts renal response and survival. Further prospective studies with uniform renal response criteria are needed to optimize the management of MIDD.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Oliver Van Oekelen, Karthik Nath, Tarek H. Mouhieddine, Tasmin Farzana, Adolfo Aleman, David T. Melnekoff, Yogita Ghodke-Puranik, Gunjan L. Shah, Alexander Lesokhin, Sergio Giralt, Santiago Thibaud, Adriana Rossi, Cesar Rodriguez, Larysa Sanchez, Joshua Richter, Shambavi Richard, Hearn J. Cho, Ajai Chari, Saad Z. Usmani, Sundar Jagannath, Urvi A. Shah, Sham Mailankody, Samir Parekh
Summary: B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR T) therapy has shown remarkable efficacy in relapsed/refractory multiple myeloma patients. However, most patients eventually relapse despite high initial response rates. This study analyzed the salvage treatments and outcomes of patients with disease recurrence after BCMA-directed CAR T therapy.
Article
Oncology
Meletios A. Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J. Bahlis, Saad Z. Usmani, Neil Rabin, Robert Z. Orlowski, Kenshi Suzuki, Torben Plesner, Sung-Soo Yoon, Dina Ben Yehuda, Paul G. Richardson, Hartmut Goldschmidt, Donna Reece, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Philippe Moreau
Summary: Based on the analysis of POLLUX, daratumumab in combination with lenalidomide and dexamethasone significantly prolonged progression-free survival in patients with relapsed or refractory multiple myeloma. The final analysis also showed that this combination therapy improved overall survival in these patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Oncology
Hareth Nahi, Saad Z. Usmani, Maria-Victoria Mateos, Niels W. C. J. van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau
LEUKEMIA & LYMPHOMA
(2023)
Article
Oncology
Thomas G. Martin, Deepu Madduri, Lida Pacaud, Saad Z. Usmani
Summary: Cilta-cel, a BCMA-targeting CAR T-cell therapy, has been approved in the USA and EU for multiple myeloma patients who have relapsed or refractory disease. It showed a high response rate and promising progression-free survival in clinical trials, with manageable adverse events. Further research is needed to explore its efficacy and safety in earlier lines of therapy and optimal sequencing in a complex treatment landscape.
Article
Oncology
Barry Paul, Michaela Liedtke, Jack Khouri, Robert Rifkin, Mitul D. Gandhi, Andrew Kin, Moshe Y. Levy, Rebecca Silbermann, Francesca Cottini, Douglas W. Sborov, Irwindeep Sandhu, Lyssa Villarreal, Michael Murphy, Lin Gu, Ann Chen, Nishanthan Rajakumaraswamy, Saad Z. Usmani
Summary: Magrolimab is a monoclonal antibody that blocks the CD47 signal on tumor cells. CD47 is overexpressed in multiple myeloma and contributes to its development. Preclinical studies have shown that blocking CD47 activates macrophages, leading to the elimination of myeloma cells. This phase II study investigates the combination of magrolimab with standard myeloma therapies in patients with relapsed/refractory MM.
Review
Oncology
Manisha Bhutani, Brandon J. Blue, Craig Cole, Ashraf Z. Badros, Saad Z. Usmani, Ajay K. Nooka, Leon Bernal-Mizrachi, Joseph Mikhael
Summary: This review examines the disparities in incidence, diagnosis, treatment access, clinical trial participation, and healthcare utilization that negatively impact outcomes for African American patients with multiple myeloma. It emphasizes the role of healthcare providers in addressing these disparities by considering historical, sociocultural, individual, and disease-related factors. The review provides insights into both biological and non-biological disparities, barriers to clinical care, and best practices for ensuring that African American patients receive optimal care.
BLOOD CANCER JOURNAL
(2023)
Article
Oncology
Anish K. Simhal, Kylee H. Maclachlan, Rena Elkin, Jiening Zhu, Larry Norton, Joseph O. Deasy, Jung Hun Oh, Saad Z. Usmani, Allen Tannenbaum
Summary: The study investigates the global interactions in multiple myeloma (MM) using a protein interaction network and a large dataset. The analysis reveals complex immune dysregulation associated with shorter survival.
BLOOD CANCER JOURNAL
(2023)
Meeting Abstract
Oncology
Maria-Victoria Mateos, Ajai Chari, Saad Zafar Usmani, Hartmut Goldschmidt, Katja Weisel, Keqin Qi, Anil Londhe, Sandhya Nair, Xiwu Lin, Lixia Pei, Eric Ammann, Rachel Kobos, Jennifer Smit, Trilok V. Parekh, Mary Slavcev, Philippe Moreau
JOURNAL OF CLINICAL ONCOLOGY
(2022)